Frozen copy retrieved 2026-08-20T19:15:00Z for audit 2026-08-20T21-09-12Z. Original URL: https://www.wpsdlocal6.com/health/moderna-and-merck-say-melanoma-vaccine-succeeded-in-large-trial/article_b606be24-ef9a-43cb-9769-73905e9233a1.html. The Stochastic Parrot does not host or redistribute; this snapshot exists solely so that quoted spans remain verifiable if the original page changes. Character offsets below index into this plain text; highlighted spans are the quotes cited in the audit.

Moderna and Merck say melanoma vaccine succeeded in large trial

CNN (via CNN Newsource syndicated reprint on WPSD Local 6) · back to the audit
VERBATIM (per left-bucket scout, contiguous paragraphs 1-3 + non-contiguous fragments):

"(CNN) — A personalized mRNA cancer vaccine combined with the immunotherapy Keytruda succeeded in a late-stage trial for the deadly skin cancer melanoma, its makers said Wednesday, potentially opening up a new way of treating the disease."

"The study is ongoing, but interim results found that the treatment, intismeran, met both its primary target of reducing cancer recurrence and its secondary goal of keeping cancers from spreading to other parts of the body."

"The results are "as big a day for humanity as Nov. 16, 2020," when Moderna released late-stage clinical trial results showing that its Covid-19 vaccine worked, the company's chief executive, Stephane Bancel, told CNN Wednesday. "This is a new chapter in cancer care.""

Non-contiguous verbatim fragments:
- "Wednesday's announcement sent Moderna's shares surging 160%."
- "The companies said they will present their results at an upcoming medical meeting and share them with regulators."
- "Moderna said the company and partner Merck aim to file for approval from regulators within months."
- "The companies said no new safety signals have emerged in the trial."
- "Previous studies showed that the most common side effects were fatigue, pain at the injection site and chills."
- "Experts say major safety concerns are unfounded."
- Federal funding for mRNA has been "slashed during President Donald Trump's second administration, driving concerns that mRNA innovation would stall"; HHS last year "canceled a $590 million deal with Moderna to develop an mRNA-based vaccine against emerging pandemic influenza"; "The latter move involved the cancellation of 22 separate contracts."
- Karen Knudsen (CEO, Parker Institute for Cancer Immunotherapy), per the article: "The positive hit here leads us into truly this next phase in immunotherapy" and "This is an auspicious start — this is where things begin."

AUDIT NOTE: The CNN article contains NO sentence explicitly stating that detailed data or overall-survival results were not released; the closest is the "present their results at an upcoming medical meeting" line. Frames the trial as having "succeeded" (definitive). Carries the Bancel "as big a day for humanity as Nov. 16, 2020" Covid comparison and the 160% stock figure and the Trump-administration funding-pushback details ($590M deal, 22 BARDA contracts). Original CNN URL (edition.cnn.com) was geo-blocked in the fetch environment; body captured via the CNN Newsource reprint carrying the original CNN byline (Meg Tirrell, Jamie Gumbrecht, and Reuters) and headline.